ESMO Advanced Course on Deep Dive in CDK4-6 Inhibitors Data in Breast Cancer 2023: Dubai

Learning objectives

• Understanding the function and biology of CDK4-6 in malignant breast cancer cells
• Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4-6 inhibition in breast cancer, both in the metastatic setting
• Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4-6 inhibition
• Providing an outlook of potential integration of CDK 4-6 inhibitors in the adjuvant setting
• Discussing clinical cancer cases to integrate use of CDK 4-6 inhibitors in clinical practice

Download the programme

Accreditation

The programme of this event has been accredited with 6 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

• Giuseppe Curigliano, Italy
• Barbara Pistilli, France